A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates

Naoto Yoshino, Fabien X S Lü, Kohtaro Fujihashi, Yukari Hagiwara, Kosuke Kataoka, Ding Lu, Linda Hirst, Mitsuo Honda, Frederik W. Van Ginkel, Yoshifumi Takeda, Chris J Miller, Hiroshi Kiyono, Jerry R. McGhee

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4+) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine.

Original languageEnglish (US)
Pages (from-to)6850-6857
Number of pages8
JournalJournal of Immunology
Volume173
Issue number11
StatePublished - Dec 1 2004

Fingerprint

AIDS Vaccines
Mucosal Immunity
Primates
HIV-1
Nose
Immunoglobulin A
Cholera Toxin
Macaca
Lymphoid Tissue
Macaca mulatta
Interleukin-4
Haplorhini
Immunoglobulin G
Viruses
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Yoshino, N., Lü, F. X. S., Fujihashi, K., Hagiwara, Y., Kataoka, K., Lu, D., ... McGhee, J. R. (2004). A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of Immunology, 173(11), 6850-6857.

A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. / Yoshino, Naoto; Lü, Fabien X S; Fujihashi, Kohtaro; Hagiwara, Yukari; Kataoka, Kosuke; Lu, Ding; Hirst, Linda; Honda, Mitsuo; Van Ginkel, Frederik W.; Takeda, Yoshifumi; Miller, Chris J; Kiyono, Hiroshi; McGhee, Jerry R.

In: Journal of Immunology, Vol. 173, No. 11, 01.12.2004, p. 6850-6857.

Research output: Contribution to journalArticle

Yoshino, N, Lü, FXS, Fujihashi, K, Hagiwara, Y, Kataoka, K, Lu, D, Hirst, L, Honda, M, Van Ginkel, FW, Takeda, Y, Miller, CJ, Kiyono, H & McGhee, JR 2004, 'A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates', Journal of Immunology, vol. 173, no. 11, pp. 6850-6857.
Yoshino N, Lü FXS, Fujihashi K, Hagiwara Y, Kataoka K, Lu D et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of Immunology. 2004 Dec 1;173(11):6850-6857.
Yoshino, Naoto ; Lü, Fabien X S ; Fujihashi, Kohtaro ; Hagiwara, Yukari ; Kataoka, Kosuke ; Lu, Ding ; Hirst, Linda ; Honda, Mitsuo ; Van Ginkel, Frederik W. ; Takeda, Yoshifumi ; Miller, Chris J ; Kiyono, Hiroshi ; McGhee, Jerry R. / A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. In: Journal of Immunology. 2004 ; Vol. 173, No. 11. pp. 6850-6857.
@article{801615497182438b87e12beb5010b78c,
title = "A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates",
abstract = "The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4+) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine.",
author = "Naoto Yoshino and L{\"u}, {Fabien X S} and Kohtaro Fujihashi and Yukari Hagiwara and Kosuke Kataoka and Ding Lu and Linda Hirst and Mitsuo Honda and {Van Ginkel}, {Frederik W.} and Yoshifumi Takeda and Miller, {Chris J} and Hiroshi Kiyono and McGhee, {Jerry R.}",
year = "2004",
month = "12",
day = "1",
language = "English (US)",
volume = "173",
pages = "6850--6857",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates

AU - Yoshino, Naoto

AU - Lü, Fabien X S

AU - Fujihashi, Kohtaro

AU - Hagiwara, Yukari

AU - Kataoka, Kosuke

AU - Lu, Ding

AU - Hirst, Linda

AU - Honda, Mitsuo

AU - Van Ginkel, Frederik W.

AU - Takeda, Yoshifumi

AU - Miller, Chris J

AU - Kiyono, Hiroshi

AU - McGhee, Jerry R.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4+) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine.

AB - The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4+) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine.

UR - http://www.scopus.com/inward/record.url?scp=9144264269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144264269&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 6850

EP - 6857

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -